We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+8.9%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
+$125M
Cap. Flow
+$100M
Cap. Flow %
7.26%
Top 10 Hldgs %
41.14%
Holding
237
New
73
Increased
38
Reduced
39
Closed
63

Top Buys

Rank Stock Value
1
MIST icon
Milestone Pharmaceuticals
MIST
+$12.5M
2
ETNB
89bio
ETNB
+$10.8M
3
IMTX icon
Immatics
IMTX
+$6.72M
4
BMY icon
Bristol-Myers Squibb
BMY
+$6.02M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$5.91M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$15.7M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$12.5M
3
KURA icon
Kura Oncology
KURA
+$10.1M
4
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$9.46M
5
ZGNX
Zogenix, Inc.
ZGNX
+$7.96M

Sector Composition

Rank Sector Weight
1 Healthcare 25.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
26
Ocular Therapeutix
OCUL
$1.81B
$13.1M 0.95%
1,716,293
-339,684
-17% -$2.82M
CYRX icon
27
CALL
CryoPort
CYRX
$760M
$12.9M 0.94%
+272,900
New +$11.1M
MIST icon
28
Milestone Pharmaceuticals
MIST
$136M
$12.8M 0.92%
+1,743,545
New +$12.5M
TARA icon
29
Protara Therapeutics
TARA
$220M
$12.2M 0.88%
722,443
+194,479
+37% +$4.51M
CYRX icon
30
PUT
CryoPort
CYRX
$760M
$11.8M 0.86%
+250,000
New +$10.1M
ZYME icon
31
PUT
Zymeworks
ZYME
$1.61B
$11.4M 0.83%
245,000
+32,200
+15% +$1.11M
RETA
32
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$11.4M 0.83%
117,100
-50,000
-30% -$6.25M
IMVT icon
33
Immunovant
IMVT
$7.87B
$11.3M 0.82%
321,887
+39,724
+14% +$1.19M
AIMT
34
PUT
DELISTED
Aimmune Therapeutics
AIMT
$11.2M 0.81%
+326,500
New +$6.95M
TCON
35
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$11.2M 0.81%
+108,127
New +$5.79M
SCPH
36
DELISTED
scPharmaceuticals
SCPH
$11M 0.8%
1,481,147
+12,500
+0.9% +$97.7K
BDTX icon
37
Black Diamond Therapeutics
BDTX
$95.1M
$10.9M 0.79%
358,941
+181,397
+102% +$5.52M
MPT
38
PUT
Medical Properties Trust
MPT
$2.75B
$10.6M 0.77%
600,000
– –
CRSP icon
39
PUT
CRISPR Therapeutics
CRSP
$4.73B
$9.64M 0.7%
115,300
-63,800
-36% -$5.66M
INCY icon
40
PUT
Incyte
INCY
$24.3B
$8.97M 0.65%
+100,000
New +$9.65M
ETNB
41
DELISTED
89bio
ETNB
$8.73M 0.63%
+340,236
New +$10.8M
KYNB
42
PUT
Kyntra Bio
KYNB
$27.4M
$8.3M 0.6%
8,076
+4,876
+152% +$5.25M
KYNB
43
CALL
Kyntra Bio
KYNB
$27.4M
$8.22M 0.6%
8,000
– –
ARDX icon
44
Ardelyx
ARDX
$1.23B
$8.04M 0.58%
1,530,436
+137,871
+10% +$829K
ALNY icon
45
PUT
Alnylam Pharmaceuticals
ALNY
$26.9B
$7.28M 0.53%
+50,000
New +$7.11M
GOSS icon
46
Gossamer Bio
GOSS
$81.9M
$7.23M 0.52%
582,494
-121,505
-17% -$1.61M
DCPH
47
CALL
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$7.18M 0.52%
+140,000
New +$6.86M
SAGE
48
DELISTED
Sage Therapeutics
SAGE
$7.1M 0.51%
116,151
-85,000
-42% -$4.31M
SBBP
49
DELISTED
Strongbridge Biopharma plc.
SBBP
$7.06M 0.51%
3,362,242
+91,004
+3% +$307K
NBP
50
NovaBridge Biosciences American Depositary Shares
NBP
$185M
$7.05M 0.51%
+150,000
New +$4.95M
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Ikarian Capital held 237 positions worth $1.38B, up 10% from $1.26B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Ikarian Capital deployed $100M of net new capital in Q3 2020, opening 73 new positions and adding to 38 existing holdings. Its largest new stake was Milestone Pharmaceuticals: 1,743,545 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 25% a quarter earlier.

On the sell side, the largest reduction was BioXcel Therapeutics, an estimated $12.5M trimmed.

  • Ikarian Capital's largest Q3 2020 buy was Milestone Pharmaceuticals: 1,743,545 shares worth $12.8M.
  • Ikarian Capital added most to Kiniksa Pharmaceuticals in Q3 2020, an estimated $5.91M increase.
  • Ikarian Capital's biggest Q3 2020 reduction was BioXcel Therapeutics, cutting an estimated $12.5M.
  • Ikarian Capital fully exited Blueprint Medicines in Q3 2020, selling an estimated $15.7M.
  • Ikarian Capital's ten largest holdings make up 41% of its $1.38B portfolio in Q3 2020.
  • Ikarian Capital opened 73 new positions and closed 63 in Q3 2020.
  • Ikarian Capital's portfolio value rose 10% quarter-over-quarter to $1.38B.

Based on Ikarian Capital's 13F filing for Q3 2020, filed 16 Nov 2020.